Agalsidase beta - Biologic Drug Details

Summary for agalsidase beta

Tradenames:	1
High Confidence Patents:	1
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for agalsidase beta

Recent Clinical Trials for agalsidase beta

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
ISU Abxis Co., Ltd.	Phase 3
Bio Sidus SA	Phase 3
Genzyme, a Sanofi Company	Phase 3

See all agalsidase beta clinical trials

Pharmacology for agalsidase beta

Established Pharmacologic Class	Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme
Chemical Structure	alpha-Glucosidases

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for agalsidase beta Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for agalsidase beta Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genzyme Corporation	FABRAZYME	agalsidase beta	For Injection	103979		2010-10-24	DrugPatentWatch analysis and company disclosures
Genzyme Corporation	FABRAZYME	agalsidase beta	For Injection	103979		2012-01-17	DrugPatentWatch analysis and company disclosures
Genzyme Corporation	FABRAZYME	agalsidase beta	For Injection	103979		2012-11-30	DrugPatentWatch analysis and company disclosures
Genzyme Corporation	FABRAZYME	agalsidase beta	For Injection	103979		2014-06-17	DrugPatentWatch analysis and company disclosures
Genzyme Corporation	FABRAZYME	agalsidase beta	For Injection	103979		2014-06-17	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for agalsidase beta Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genzyme Corporation	FABRAZYME	agalsidase beta	For Injection	103979		2036-12-20	Patent claims search
Genzyme Corporation	FABRAZYME	agalsidase beta	For Injection	103979		2036-08-10	Patent claims search
Genzyme Corporation	FABRAZYME	agalsidase beta	For Injection	103979		2036-06-14	Patent claims search
Genzyme Corporation	FABRAZYME	agalsidase beta	For Injection	103979		2037-06-29	Patent claims search
Genzyme Corporation	FABRAZYME	agalsidase beta	For Injection	103979		2037-12-26	Patent claims search
Genzyme Corporation	FABRAZYME	agalsidase beta	For Injection	103979		2038-12-19	Patent claims search

International Patents for agalsidase beta

Country	Patent Number	Estimated Expiration
Austria	E213020
Austria	E241010
Austria	E464386
Australia	5681794
Australia	691795
Australia	8954791

Supplementary Protection Certificates for agalsidase beta

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1390054-3	Sweden		PRODUCT NAME: AGALSIDAS BETA; REG. NO/DATE: EU/1/01/188/001 20010803
13C0064	France		PRODUCT NAME: AGALSIDASE BETA; REGISTRATION NO/DATE: EU/1/01/188/001-006 20010807
122010000028	Germany		PRODUCT NAME: AGALSIDASE ALFA IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/01/189/001 20010803
2010/021	Ireland		PRODUCT NAME: AGALSIDASE ALFA; NAT REGISTRATION NO/DATE: EU/1/01/188/001-003 20010803; FIRST REGISTRATION NO/DATE: EU/1/01/189/001 03/08/2001 EUROPEAN UNION EU/1/01/188/001-003 03/08/2001 EUROPEAN UNION EU/1/01/189/001 20010803
2013/054	Ireland		PRODUCT NAME: AGALSIDASE BETA; REGISTRATION NO/DATE: EU/1/01/188/001-006 20010803
132013902212169	Italy		AUTHORISATION NUMBER(S) AND DATE(S): EU/1/01/188, 20010803;EU/1/01/188/001-002-003, 20010803

Market Dynamics and Financial Trajectory for AGALSIDASE BETA

Last updated: April 23, 2026

Agalsidase beta is a recombinant lysosomal enzyme (beta-galactosidase) used for Fabry disease. The market has shifted from fast early uptake toward consolidation driven by: (1) patent and biosimilar/entry-risk timelines across the Fabry enzyme class, (2) payer tightening on infusion-center logistics and total cost of care, and (3) competitive pressure from substrate-reduction approaches and alternative enzyme therapies in select geographies. Financial trajectory is shaped by the balance between continued label-based demand and erosion from competitive substitutions, with revenue growth increasingly dependent on retention, channel execution, and contract terms rather than unit expansion.

What is the current market position for AGALSIDASE BETA?

Agalsidase beta is sold under Fabrazyme (Sanofi). It competes in enzyme replacement therapy (ERT) for Fabry disease against agalsidase alfa (marketed as Replagal; originator context varies by geography) and, in some regions, against other ERT or newly adopted Fabry treatment standards that can reduce ERT switching tolerance through cost and outcomes contracting.

Demand anchor: ERT remains the default for many patients where payer policy favors established outcomes evidence and infusion protocols. The practical buyer decision for ERT is strongly driven by:

• Infusion administration capacity (hospital/day clinic contracts)
• Total payer cost (drug + infusion + premedication + infusion-related monitoring)
• Switching restrictions tied to “stable on therapy” clauses and prior authorization criteria

What has changed structurally: Over time, Fabry therapy adoption cycles have matured. As payer and treatment guidelines stabilize around multiple options, uptake tends to slow and revenue growth relies on:

• Conversion of late-eligible cohorts and treatment-naive starts
• Retention of existing patients under contract renewal
• Geographical expansion where access is still building

How do market dynamics affect pricing, contracting, and volume?

Fabry ERT pricing is negotiated under high payer scrutiny because dosing intensity is fixed by body weight and treatment schedule, while medical costs in real-world care are also driven by infusion administration and monitoring.

Key market levers include:

1) Infusion logistics and site-of-care contracting

ERT administration costs often determine the net budget impact more than the headline acquisition cost. Payers and integrated providers increasingly negotiate for:

• Infusion center reimbursement caps
• Formulary tier placement tied to site-of-care performance
• Narrower criteria that require documentation of disease markers and prior therapy history

2) Formulary management and prior authorization friction

Agalsidase beta demand in a given geography correlates with how quickly payers approve:

• Treatment initiation in pediatric vs adult cohorts
• Switching for renal, cardiac, or neurologic deterioration
• Continuation for “nonresponse” edge cases

3) Competitive substitution risk inside the same indication class

Within Fabry ERT, substitution risk exists when payers reduce ERT acquisition cost and administrators use procurement mandates. Even without broad “automatically switch” policies, contract procurement can shift new starts away from an incumbent.

4) Guideline and outcome evidence in procurement decisions

Even when clinical evidence supports ERT broadly, procurement teams emphasize measurable endpoints tied to budget impact:

• Renal function trajectories and hospitalization frequency
• Cardiovascular event burden
• Infusion reaction rates and discontinuation

What does the financial trajectory look like for AGALSIDASE BETA?

Public financial trajectory for specific Fabry biologics depends on what Sanofi discloses by product versus by region and therapy area. For investment-grade assessment, the trajectory is typically inferred from:

• Company-reported sales for Fabrazyme
• Sanofi’s broader Rare Disease revenue performance
• Ongoing competitive and tender dynamics in major markets

Business pattern in mature ERT markets: Agalsidase beta tends to exhibit:

• Stable-to-slow growth rather than rapid expansion as the label population saturates
• Revenue sensitivity to contract cycles (tender wins/losses and reimbursement policy updates)
• Periodic step-down risk when payers introduce stricter authorization or favor lower net cost products

Financial inflection points to track in the record:

1. Patent and exclusivity landscape changes in the Fabry ERT category across major markets
2. Biosimilar/entry probability for comparable enzyme replacement products
3. Formulary decisions in top prescribing markets
4. Patient retention during contract renegotiations

Because the user request is specifically “Market dynamics and financial trajectory for the biologic drug: AGALSIDASE BETA,” a full quantified revenue time series would require product-level sales data over multiple reporting years. Without those figures available in the source material used here, the analysis is limited to trajectory drivers rather than a year-by-year revenue table.

How does competition reshape the runway (vs. within-class and outside-class)?

Agalsidase beta faces two competition channels:

Within-class competition (other Fabry ERT options)

• ERT competitors can win through net price and procurement logistics.
• Even when clinical outcomes are comparable, payers can prefer the lower net-cost alternative for new starts and, in some cases, for switch-eligible stable patients.

Outside-class competition (new mechanisms)

If payers and clinicians adopt alternative Fabry approaches in a market, ERT enrollment can shift. This is typically slower than biosimilar substitution but can still pressure long-run unit growth.

Where is the commercial risk concentrated?

For ERT biologics, risk concentrates in:

• Major payer networks (tender-led procurement can change contract economics quickly)
• High-cost infusion regions where administration reimbursement is contested
• Centers with consolidated buying power that can standardize preferred therapies

For agalsidase beta specifically, the commercial risk profile depends on whether Fabrazyme’s net realized price remains favorable relative to alternatives and whether continuation clauses prevent meaningful churn.

What should investors track to underwrite the next 12 to 36 months?

A rigorous monitoring set for agalsidase beta should focus on:

1. Sanofi product-level Fabrazyme sales trend (quarterly and annual)
2. Region-specific payer policy shifts affecting ERT access
3. Contract renewal outcomes with major integrated delivery networks
4. Switching patterns in real-world datasets (new starts vs continuation)
5. Competitive tender announcements in top markets

The thesis for sustained growth is retention-led plus selective new patient starts; the thesis for downside is net price compression plus authorization tightening.

Key Takeaways

• Agalsidase beta (Fabrazyme) competes in a mature Fabry ERT market where volume growth is limited and financial performance depends on retention and contract execution.
• Market dynamics increasingly reflect total cost of care, infusion logistics, and prior authorization policies rather than only drug acquisition pricing.
• The financial trajectory is typically stable-to-slow growth with contract cycle sensitivity; downside risk concentrates in payer tender-driven net price compression and restrictive access policies.
• Near-term underwriting hinges on product-level Fabrazyme sales trends, major payer contract outcomes, and switching behavior.

FAQs

1) Is agalsidase beta’s market primarily driven by new patient starts or patient retention?

Patient retention dominates in mature ERT markets; new starts matter most when authorization criteria and contract economics stay favorable.

2) What are the biggest commercial levers for Fabrazyme in payer negotiations?

Net realized price and site-of-care infusion economics, including total budget impact and contract terms that govern initiation and continuation.

3) How does within-class competition affect agalsidase beta revenue?

It pressures new starts first through procurement and formulary positioning, with slower effects on continued patients unless contracts allow broader switching.

4) What external factors can change Fabrazyme’s financial trajectory faster than clinical adoption?

Payer tender cycles, prior authorization policy revisions, and administration reimbursement changes that alter effective total cost.

5) What indicators most directly signal revenue risk?

Declines in product-level Fabrazyme sales growth rates, evidence of churn or reduced new starts, and contract outcomes in top markets that reduce net realized price.

---

References

[1] Sanofi. Fabrazyme (agalsidase beta) product information and updates. Sanofi official website.
[2] FDA. Fabrazyme (agalsidase beta) Prescribing Information. U.S. Food and Drug Administration.
[3] EMA. Fabrazyme (agalsidase beta) product information (where available). European Medicines Agency.
[4] WHO Collaborating Centre for Drug Statistics Methodology. ATC classification reference for Fabry therapies (context). World Health Organization.